Christian N. Montalbetti

Rome, 00071, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Discovery and Optimization of IRBM-Z-2, an Allosteric Zika Virus NS2B-NS3 Protease Inhibitor Exhibiting In Vivo Efficacy.

Discovery and Optimization of IRBM-Z-2, an Allosteric Zika Virus NS2B-NS3 Protease Inhibitor Exhibiting In Vivo Efficacy.

Journal: Journal of medicinal chemistry

Published: May 29, 2026

Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers.

Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers.

Journal: Journal of medicinal chemistry

Published: April 13, 2026

An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models.

An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models.

Journal: Nature communications

Published: May 15, 2025

Novel azabicyclic series of potent SHP2 allosteric inhibitors.

Novel azabicyclic series of potent SHP2 allosteric inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 14, 2025

Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors.

Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors.

Journal: ACS medicinal chemistry letters

Published: February 21, 2023

SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.

SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.

Journal: Bioorganic & medicinal chemistry

Published: July 30, 2021

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: March 05, 2019

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Journal: Journal of medicinal chemistry

Published: February 16, 2018

Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K).

Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K).

Journal: Journal of medicinal chemistry

Published: December 23, 2016

Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.

Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.

Journal: ChemMedChem

Published: January 14, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026